




PHARMACEUTICAL 2021

Kintara Therapeutics Inc.
Rank 373 of 402





PHARMACEUTICAL 2021

Kintara Therapeutics Inc.
Rank 373 of 402

The relative strengths and weaknesses of Kintara Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kintara Therapeutics Inc. compared to the market average is the variable Cost of Goods Sold, increasing the Economic Capital Ratio by 8.7% points. The greatest weakness of Kintara Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 216% points.

The company's Economic Capital Ratio, given in the ranking table, is -309%, being 356% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	2,851
Cost of Goods Sold	0
Intangible Assets	2.1
Liabilities, Current	0
Liabilities, Non-Current	0
Other Assets	85
Other Compr. Net Income	0
Other Expenses	1,054
Other Liabilities	2,675
Other Net Income	72
Other Revenues	0
Property and Equipment	0
Research and Development	3,630
Selling, General and Administrative Expense	4,515

Output Variable	Value in 1000 USD
Assets	2,938
Liabilities	2,675
Expenses	9,198
Revenues	0
Stockholders Equity	263
Net Income	-9,126
Comprehensive Net Income	-9,126
Economic Capital Ratio	-309%